Evidence for a crucial role of neutrophil-derived serine proteases in the inactivation of interleukin-6 at sites of inflammation

被引:50
作者
Bank, U
Küpper, B
Reinhold, D
Hoffmann, T
Ansorge, S
机构
[1] Otto Von Guericke Univ, Ctr Internal Med, Inst Immunol, D-39120 Magdeburg, Germany
[2] Otto Von Guericke Univ, Ctr Internal Med, Inst Expt Internal Med, D-39120 Magdeburg, Germany
[3] Probiodrug, D-06120 Halle, Germany
来源
FEBS LETTERS | 1999年 / 461卷 / 03期
关键词
D O I
10.1016/S0014-5793(99)01466-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The bioactivity of interleukin-6 (IL-6) was found to be dramatically reduced in fluids from sites of inflammation, Here, we provide evidence that the neutrophil-derived serine proteases elastase, proteinase 3 and cathepsin G are mainly involved in its degradation and subsequent inactivation. The initially hydrolyzed peptide bonds were detected to be Val(11)-Ala(12) and Leu(19)-Thr(20) (elastase), Phe(78)-Asn(79) (cathepsin G) and Ala(145)-Ser(146) (proteinase 3), The soluble IL-6 receptor elicits a protective effect against the IL-6 inactivation by cathepsin G only. The inactivation of IL-6 by neutrophil-derived serine proteases might act as a feedback mechanism terminating the IL-6-induced activation of neutrophils. (C) 1999 Federation of European Biochemical Societies.
引用
收藏
页码:235 / 240
页数:6
相关论文
共 40 条
[31]   IN-VITRO PROCESSING OF HUMAN TUMOR-NECROSIS-FACTOR-ALPHA [J].
ROBACHEGALLEA, S ;
MORAND, V ;
BRUNEAU, JM ;
SCHOOT, B ;
TAGAT, E ;
REALO, E ;
CHOUAIB, S ;
ROMANROMAN, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (40) :23688-23692
[32]  
SALVESEN GS, 1999, HDB PROTEOLYTIC ENZY, pCH16
[33]   CATHEPSIN-G AND LEUKOCYTE ELASTASE INACTIVATE HUMAN TUMOR-NECROSIS-FACTOR AND LYMPHOTOXIN [J].
SCUDERI, P ;
NEZ, PA ;
DUERR, ML ;
WONG, BJ ;
VALDEZ, CM .
CELLULAR IMMUNOLOGY, 1991, 135 (02) :299-313
[34]  
Sehgal PB, 1996, P SOC EXP BIOL MED, V213, P238
[35]   SUBCELLULAR-LOCALIZATION AND DYNAMICS OF MAC-1 (ALPHA(M)BETA(2)) IN HUMAN NEUTROPHILS [J].
SENGELOV, H ;
KJELDSEN, L ;
DIAMOND, MS ;
SPRINGER, TA ;
BORREGAARD, N .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (03) :1467-1476
[36]  
SIRONI M, 1989, J IMMUNOL, V142, P549
[37]   1.9 angstrom crystal structure of interleukin 6: Implications for a novel mode of receptor dimerization and signaling [J].
Somers, W ;
Stahl, M ;
Seehra, JS .
EMBO JOURNAL, 1997, 16 (05) :989-997
[38]   IL-6 and APPs: anti-inflammatory and immunosuppressive mediators [J].
Tilg, H ;
Dinarello, CA ;
Mier, LW .
IMMUNOLOGY TODAY, 1997, 18 (09) :428-432
[39]   Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity [J].
Toniatti, C ;
Cabibbo, A ;
Sporeno, E ;
Salvati, AL ;
Cerretani, M ;
Serafini, S ;
Lahm, A ;
Cortese, R ;
Ciliberto, G .
EMBO JOURNAL, 1996, 15 (11) :2726-2737
[40]   PATHOLOGICAL CONCENTRATIONS OF INTERLEUKIN-6 INHIBIT T-CELL RESPONSES VIA INDUCTION OF ACTIVATION OF TGF-BETA [J].
ZHOU, DH ;
MUNSTER, A ;
WINCHURCH, RA .
FASEB JOURNAL, 1991, 5 (11) :2582-2585